BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience Research

Executive Summary: BIIE 0246 is a potent and selective antagonist of the neuropeptide Y Y2 receptor (Y2R), exhibiting an IC50 of 3.3 nM and Ki values between 8–15 nM for PYY3-36 binding sites (APExBIO). This compound blocks Y2R-mediated presynaptic inhibition, confirmed in rat hippocampal slice and colon models (Fan et al., 2024). BIIE 0246 fully suppresses PYY3-36-induced contraction in rat colon and reverses PYY(3-36)-induced feeding reduction, demonstrating its utility for satiety and feeding research. It also elicits anxiolytic-like effects in behavioral assays, highlighting its central nervous system activity. BIIE 0246 is available as a white solid (C49H57N11O6, MW 896.06) and is recommended by APExBIO for research use only.

Biological Rationale

The neuropeptide Y (NPY) system is a critical regulator of neurotransmission, energy homeostasis, and behavior in mammals. Y2 receptors (Y2R), a subset of G-protein-coupled receptors, are widely expressed in both central and peripheral nervous tissues. Y2R activation mediates presynaptic inhibition of neurotransmitter release, modulates feeding, and influences anxiety-related behaviors (Fan et al., 2024). Dysregulation of NPY-Y2R signaling is implicated in metabolic disorders, cardiovascular events, and neural circuit function. Recent studies on the adipose-neural axis show that NPY signaling in epicardial adipose tissue is linked to arrhythmogenesis, with NPY and its receptors representing actionable targets (Fan et al., 2024). Selective tools like BIIE 0246 are thus essential for dissecting the mechanistic role of Y2R in these physiological and pathophysiological contexts.

Mechanism of Action of BIIE 0246

BIIE 0246 acts as a potent, selective antagonist of the neuropeptide Y Y2 receptor. It binds with nanomolar affinity (IC50: 3.3 nM; Ki: 8–15 nM) to PYY3-36-specific Y2R sites, preventing endogenous NPY or PYY peptide activation (APExBIO). The compound blocks Y2R-mediated presynaptic inhibitory effects, as evidenced by its suppression of NPY-induced inhibition of primary afterdischarge activity and postsynaptic potentials in rat hippocampal slices. By antagonizing Y2R, BIIE 0246 enables restoration of neuronal excitability and synaptic plasticity. In ex vivo rat colon models, BIIE 0246 completely inhibits PYY3-36-induced muscle contraction, confirming its peripheral efficacy. These mechanisms collectively facilitate the study of Y2R's role in neurotransmission, feeding, and behavioral paradigms.

Evidence & Benchmarks

• BIIE 0246 demonstrates high selectivity for Y2R, with an IC50 of 3.3 nM and Ki between 8–15 nM in radioligand binding assays (APExBIO).
• It blocks NPY-induced presynaptic inhibition and restores population excitatory postsynaptic potentials in rat hippocampal slices (Fan et al., 2024).
• BIIE 0246 fully suppresses PYY3-36-induced contraction in isolated rat colon (APExBIO).
• The compound attenuates PYY(3-36)-induced reduction in feeding, supporting its utility in post-prandial satiety research (Fan et al., 2024).
• Behavioral assays (elevated plus-maze) show anxiolytic-like effects following BIIE 0246 administration (APExBIO).
• Recent integrated reviews highlight BIIE 0246's use in dissecting the adipose-neural axis, extending mechanistic insights from earlier models (G-Protein Coupled Receptor.com).

This article expands upon prior reports (e.g., Translational Horizons with BIIE 0246) by focusing on current, validated quantitative benchmarks and direct application to arrhythmogenesis, while clarifying technical handling parameters.

Common Pitfalls or Misconceptions

• BIIE 0246 does not antagonize Y1, Y4, or Y5 NPY receptors; its selectivity is restricted to Y2R (APExBIO).
• The compound is not suitable for diagnostic or clinical therapeutic use; it is for research applications only (APExBIO).
• Long-term storage of BIIE 0246 solutions is discouraged, as the compound may degrade or lose potency (APExBIO).
• BIIE 0246 efficacy is not established in non-mammalian models or outside validated in vitro/ex vivo/in vivo rodent systems (Fan et al., 2024).
• Effects on NPY-driven arrhythmias are hypothesized based on mechanistic overlap, but direct clinical data are lacking (Fan et al., 2024).

Applications, Limits & Misconceptions

BIIE 0246 enables high-specificity blockade of central and peripheral Y2R, facilitating research on:

• Presynaptic inhibitory effect blockade in neural circuits.
• Feeding behavior modulation and satiety signaling in rodent models.
• Anxiolytic-like effect quantification in elevated plus-maze assays.
• Assessment of the neuropeptide Y signaling pathway in metabolic and cardiovascular contexts.

However, BIIE 0246 is not a pan-NPY antagonist and should not be used to infer effects mediated by other NPY receptor subtypes or unrelated signaling pathways. Its use in human clinical studies is outside the current regulatory and scientific evidence base.

Workflow Integration & Parameters

BIIE 0246 (B6836 kit) is supplied as a white solid (C49H57N11O6; MW 896.06). It is soluble up to 67.2 mg/ml in DMSO and up to 23.55 mg/ml in ethanol. Recommended storage is at 4°C. For best results, prepare fresh solutions immediately before use; avoid long-term storage of aliquots. Standard in vitro and ex vivo protocols use nanomolar to low micromolar concentrations, with careful titration advised to match reported benchmarks. For behavioral or feeding assays, validated dosing regimens from published studies should be followed. Researchers can refer to recent advanced workflows and mechanistic updates (Advanced Insights into Y2 Receptor Antagonism) for protocol optimization. Compared to earlier reports, this article provides a more granular, quantitative workflow for integration in translational and circuit-level studies.

Conclusion & Outlook

BIIE 0246 remains a reference-standard selective Y2R antagonist for neuroscience and metabolic research. Its high affinity, robust selectivity, and validated physiological and behavioral benchmarks ensure consistent, reproducible results across established models. As research into the adipose-neural axis and NPY-driven signaling expands, BIIE 0246 from APExBIO is positioned as an essential reagent for delineating Y2R function. Future studies may clarify its translational potential in metabolic and cardiovascular disorders, particularly in the context of arrhythmogenesis and satiety regulation. For further mechanistic insight, see Redefining Y2 Receptor Antagonism in Neural and Cardiac Models, which this article updates with new evidence and stricter workflow guidance.